Early Phase 1 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men, or women who are not pregnant or breastfeeding, aged 18 to 55, who either cannot become pregnant, live a completely abstinent lifestyle, or agree to use an approved form of contraception
- For certain parts of the trial (Part 1a/b and Part 2 Cohort 7): People whose body mass index (BMI — a measure of weight relative to height) falls between 18.0 and 30.0
- For the food effect portion of the trial: People who are willing to eat a single high-fat breakfast as part of testing
- For Part 2 only (schizophrenia group): People who have a stable diagnosis of schizophrenia
- For Part 2 schizophrenia participants: People whose BMI falls between 17.5 and 36.0
- For Part 2 schizophrenia participants: People whose symptom score on a standard psychiatric scale (called the PANSS) is below 80 at the initial screening appointment (confirm with trial site)
Who may not be able to join:
- For healthy participants in Part 1 and Part 2: People who have a history of, or currently have, a significant physical or mental health condition
- People who have been diagnosed with or treated for cancer in the past 7 years
- People with ongoing or long-term digestive conditions that could affect how the body processes medication
- People with a significant abnormality found on a heart tracing test (ECG)
- For Part 2: People who have a primary psychiatric diagnosis other than schizophrenia, as defined by standard diagnostic guidelines (DSM-5TR)
- People with schizophrenia whose condition has not responded to antipsychotic medications in the past, or who have previously used a medication called clozapine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Doug Feltner, MD, Neurosterix
Phone: +41 22 884 15 55
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of reported Adverse Events; Number of Adverse Events of Special Interest (AESI); Number of dose limiting treatment emergent adverse events (TEAE); Vital Signs: Change in blood pressure; Vital Signs: Change in temperature; Vital Signs: Change in respiratory rate; Vital Signs: Change in heart rate; Change in physical examination; Clinical Laboratory Tests
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.